Sign Up
Stories
Breakthrough Cancer Treatment Trial Begins
Share
ADC Therapeutics Webcast Announced
AI-Powered Cancer Drug Trials
Advanced Cancer Therapies Show Promising...
Aadi Bioscience Validates FYARRO® for PE...
Advanced Ovarian Cancer Treatment Breakt...
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
NiKang Therapeutics initiates phase 1/1b trial for NKT3447, a CDK2 inhibitor targeting cyclin E amplified cancers.
Ask a question
How does NKT3447's mechanism of action differ from existing cancer treatments?
How might the results of this trial impact the future of cancer therapy and personalized medicine?
What are the potential implications of successfully targeting cyclin E amplified cancers?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage